VITAMIN D AND OUTCOMES IN PEDIATRIC PATIENTS WITH HIGH-RISK NEUROBLASTOMA (HR-NB). AN UNTAPPED APPROACH IN PEDIATRIC CANCER

被引：0
|
作者：
Izurieta Pacheco, Ana Carolina [1 ]
Gimenez, Ana Sangros [1 ]
Martinez, Esther [1 ]
Perez, Sara [1 ]
Gorostegui, Maite [1 ]
机构：
[1] Hosp San Juan Dios, Pediat Canc Ctr Barcelona, Oncol Dept, Barcelona, Spain
来源：
PEDIATRIC BLOOD & CANCER | 2022年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO069a
引用
收藏
页码：S596 / S596
页数：1
相关论文
共 50 条
  • [21] Vitamin D Status in Children With High-risk Neuroblastoma
    Izurieta-Pacheco, Ana Carolina
    Sangros-Gimenez, Ana
    Martinez-Garcia, Esther
    Perez-Jaume, Sara
    Mora, Jaume
    Gorostegui-Obanos, Maite
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2023, 45 (08) : E953 - E958
  • [22] Radiation-induced lymphopenia in pediatric high-risk neuroblastoma
    Gomis Selles, E.
    Munoz Munoz, O.
    Delgado Leon, B. D.
    Cabrera Roldan, P.
    Burgueno Caballero, A. M.
    Lopez Guerra, J. L.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S1273 - S1274
  • [23] OUTCOMES OF HIGH-RISK PEDIATRIC PATIENTS UNDERGOING LOW-RISK SURGERY
    Cheon, E.
    Longhini, A.
    Lee, J.
    Hajduk, J.
    De Oliveira, G.
    Jagannathan, N.
    ANESTHESIA AND ANALGESIA, 2016, 122
  • [24] Efficacy of naxitamab in patients with refractory/relapse (R/R) high-risk neuroblastoma (HR-NB) by bone/bone marrow (BM) evaluation, potential sites of residual disease.
    Kushner, Brian H.
    Morgenstern, Daniel A.
    Nysom, Karsten
    Bear, Melissa K.
    Tornoe, Karen
    Losic, Nedjad
    Mora, Jaume
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Safety and efficacy of naxitamab plus modified dosing of GM-CSF for patients with high-risk neuroblastoma (HR-NB) in first complete remission (CR) or with primary refractory disease
    Kushner, Brian H.
    Modak, Shakeel
    Basu, Ellen M.
    Cardenas, Fiorella Iglesias
    Kramer, Kim
    Roberts, Stephen S.
    Cheung, Nai-Kong V.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] Immunotherapy with recombinant human IL-2 (rHuIL-2) after autologous stem cell transplantation (ASCT) for high-risk neuroblastoma (HR-NB).
    Pession, A
    Prete, A
    Locatelli, F
    Melchionda, F
    Messina, C
    Bonetti, F
    Alvisi, P
    Cordero, L
    Rondelli, R
    Rabusin, M
    Favre, BC
    Arrighini, A
    Paolucci, P
    Millanaccio, C
    Bernardi, D
    Paolucci, G
    BONE MARROW TRANSPLANTATION, 1998, 21 : S222 - S222
  • [27] Assessment of Late Pulmonary Outcomes and Exercise Capacity Among Pediatric Survivors of High-Risk Neuroblastoma
    Stone, A. E.
    Friedman, D. Novetsky
    Kushner, B. H.
    Wolden, S.
    Modak, S.
    LaQuaglia, M. P.
    Costello, J.
    Veler, H.
    Wu, X.
    Cheung, N.
    Sklar, C. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [28] Management of Busulfan-Induced Lung Injury in Pediatric Patients with High-Risk Neuroblastoma
    Castelli, Sveva
    Thorwarth, Anne
    van Schewick, Claudia
    Wendt, Anke
    Astrahantseff, Kathy
    Szymansky, Annabell
    Lodrini, Marco
    Veldhoen, Simon
    Gratopp, Alexander
    Mall, Marcus A.
    Eggert, Angelika
    Deubzer, Hedwig E.
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (19)
  • [29] Nutritional Assessments in Pediatric Patients with High Risk Neuroblastoma
    Mandava, Mamatha
    Thigpen, Haley
    Heh, Julie
    Judd, Leah
    Littleton, Amanda
    Hudspeth, Michelle
    Kraveka, Jackie
    Jaroscak, Jennifer Joi
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [30] Adoptive immunotherapy with recombinant human IL-2 (rHuIL-2) after autologous stem cell transplantation (ASCT) for high-risk neuroblastoma (HR-NB).
    Pession, A
    Prete, A
    Locatelli, F
    Alvisi, P
    Garaventa, A
    Messina, C
    Pierinelli, S
    Bonetti, F
    Cordero, L
    Favre, C
    Arrighini, A
    Rondelli, R
    DeBernandi, B
    Paolucci, G
    EXPERIMENTAL HEMATOLOGY, 1996, 24 (09) : 374 - 374
12345